港股详情

本页面由TTMF Limited提供服务

百利天恒待上市

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：4.22亿

香港流通股本：4.22亿

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：-19.00%

总资产收益率：-5.41%

市净率：0.00

市盈率(LYR):- -

市销率: 0.00

1

开始申购

11/07

2

申购截止

11/12 09:30

3

公布中签

11/13

4

暗盘

12/31 16:15 - 18:30

5

挂牌上市

11/17

总览公司新闻资讯公告

价格范围

347.50 ~ 389.00 HKD

发行价

- -

发行量

863.43万

预计市值

1,464.74亿 ~ 1,639.67亿 HKD

最低申购数量

100

承销商

高盛(亚洲)有限责任公司

查看招股说明书

新闻资讯

百利天恒：iza-bren联合用药获2个II/III期临床试验批准

每日经济新闻

估值锚点切换：百利天恒iza-bren如何凭一己之力推高全球双抗ADC的天花板？

百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准

百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02615"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1775030400000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"04-01 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1775007000000,1775016000000],[1775019600000,1775030400000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":312.9,"timestamp":1775026800000,"preClose":278,"halted":0,"volume":3432400,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-19.00%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.204,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"百利天恆","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"高盛(亚洲)有限责任公司","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1775045064699,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1774967976661,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false,"showClawback":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624123594","title":"百利天恒：iza-bren联合用药获2个II/III期临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624123594","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624123594?lang=zh_cn&edition=fundamental","pubTime":"2026-04-01 18:06","pubTimestamp":1775038011,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月1日，百利天恒(688506.SH)公告称，公司近日收到国家药监局签发的2个《药物临床试验批准通知书》，公司自主研发的创新生物药iza-bren(EGFR×HER3双抗ADC)的2个联合用药方案获得批准。获批适应症包括：联合阿比特龙±奥拉帕利、联合奥拉帕利用于去势抵抗性前列腺癌；联合贝伐珠单抗±化疗、联合奥拉帕利±贝伐珠单抗±化疗用于晚期卵巢癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692048171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692048171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK4134","BK0239","III","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622889113","title":"估值锚点切换：百利天恒iza-bren如何凭一己之力推高全球双抗ADC的天花板？","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889113","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622889113?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:10","pubTimestamp":1774487444,"startTime":"0","endTime":"0","summary":"中国医药创新的领跑时代已至，百利天恒正站在潮头，率先拉开平台化估值重构的大幕，更为中国创新药的全球价值重估写下全新标杆。","market":"fut","thumbnail":"https://img2.gelonghui.com/b17e2-af7974ae-2386-45d1-ba16-2971b9a6c446.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-af7974ae-2386-45d1-ba16-2971b9a6c446.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4186037","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["91194","BK4231","BK4080","02615","688506","ADC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621371933?lang=zh_cn&edition=fundamental","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02615","688506","LU1815336091.USD","BK0239","91194","BK1161","159992","BL","06978","BK4023","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620624216","title":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2620624216","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620624216?lang=zh_cn&edition=fundamental","pubTime":"2026-03-19 13:35","pubTimestamp":1773898522,"startTime":"0","endTime":"0","summary":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677222420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":45,"pageCount":1,"totalSize":178,"code":"91000000","status":"200"}]}}